SkinBioTherapeutics PLC
SkinBioTherapeutics plc, a life science company, engages in research and development, and commercialization of technology that harnesses the microbiome for human health in the United Kingdom, the United States, Europe, and internationally. It develops SkinBiotix technology that harnesses microbiome to promote wound healing and reduce the risk of infection; AxisBiotix-Ps, which alleviate the sympt… Read more
SkinBioTherapeutics PLC (SBTX) - Net Assets
Latest net assets as of June 2025: GBX9.42 Million GBX
Based on the latest financial reports, SkinBioTherapeutics PLC (SBTX) has net assets worth GBX9.42 Million GBX as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (GBX12.13 Million) and total liabilities (GBX2.71 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | GBX9.42 Million |
| % of Total Assets | 77.68% |
| Annual Growth Rate | 42.46% |
| 5-Year Change | 80.61% |
| 10-Year Change | N/A |
| Growth Volatility | 308.58 |
SkinBioTherapeutics PLC - Net Assets Trend (2016–2025)
This chart illustrates how SkinBioTherapeutics PLC's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for SkinBioTherapeutics PLC (2016–2025)
The table below shows the annual net assets of SkinBioTherapeutics PLC from 2016 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-06-30 | GBX9.42 Million | +217.15% |
| 2024-06-30 | GBX2.97 Million | +48.87% |
| 2023-06-30 | GBX1.99 Million | -19.41% |
| 2022-06-30 | GBX2.48 Million | -52.54% |
| 2021-06-30 | GBX5.22 Million | +111.50% |
| 2020-06-30 | GBX2.47 Million | -35.28% |
| 2019-06-30 | GBX3.81 Million | +10.73% |
| 2018-06-30 | GBX3.44 Million | -18.34% |
| 2017-06-30 | GBX4.21 Million | +980.82% |
| 2016-06-30 | GBX389.85K | -- |
Equity Component Analysis
This analysis shows how different components contribute to SkinBioTherapeutics PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1469098500.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (June 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | GBX2.59 Million | 27.47% |
| Other Comprehensive Income | GBX438.59K | 4.66% |
| Other Components | GBX21.09 Million | 223.88% |
| Total Equity | GBX9.42 Million | 100.00% |
SkinBioTherapeutics PLC Competitors by Market Cap
The table below lists competitors of SkinBioTherapeutics PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Ellcot Spinning Mills Ltd
KAR:ELSM
|
$3.90K |
|
5 Year Fixed Rate
KAR:P05FRR100529
|
$3.90K |
|
PT Astra Agro Lestari Tbk
MU:ASX
|
$3.92K |
|
Vinacomin Mong Duong Coal JSC
VN:MDC
|
$3.92K |
|
Towellers Ltd
KAR:TOWL
|
$3.90K |
|
Gol Intelligent Airlines Inc
STU:GOQN
|
$3.90K |
|
K3 Business Technology Group PLC
LSE:KBT
|
$3.90K |
|
67GX
LSE:67GX
|
$3.89K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in SkinBioTherapeutics PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,969,881 to 9,419,097, a change of 6,449,216 (217.2%).
- Net loss of 696,253 reduced equity.
- New share issuances of 6,055,469 increased equity.
- Other comprehensive income increased equity by 1.
- Other factors increased equity by 1,089,999.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | GBX-696.25K | -7.39% |
| Share Issuances | GBX6.06 Million | +64.29% |
| Other Comprehensive Income | GBX1.00 | +0.0% |
| Other Changes | GBX1.09 Million | +11.57% |
| Total Change | GBX- | 217.15% |
Book Value vs Market Value Analysis
This analysis compares SkinBioTherapeutics PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 254.02x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 3205.73x to 254.02x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-06-30 | GBX0.00 | GBX10.50 | x |
| 2017-06-30 | GBX0.04 | GBX10.50 | x |
| 2018-06-30 | GBX0.03 | GBX10.50 | x |
| 2019-06-30 | GBX0.03 | GBX10.50 | x |
| 2020-06-30 | GBX0.02 | GBX10.50 | x |
| 2021-06-30 | GBX0.04 | GBX10.50 | x |
| 2022-06-30 | GBX0.02 | GBX10.50 | x |
| 2023-06-30 | GBX0.01 | GBX10.50 | x |
| 2024-06-30 | GBX0.02 | GBX10.50 | x |
| 2025-06-30 | GBX0.04 | GBX10.50 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently SkinBioTherapeutics PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -7.39%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -15.01%
- • Asset Turnover: 0.38x
- • Equity Multiplier: 1.29x
- Recent ROE (-7.39%) is above the historical average (-51.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | -1.08% | -151.72% | 0.01x | 1.09x | GBX-43.19K |
| 2017 | -15.33% | 0.00% | 0.00x | 1.03x | GBX-1.07 Million |
| 2018 | -24.53% | 0.00% | 0.00x | 1.06x | GBX-1.19 Million |
| 2019 | -30.13% | 0.00% | 0.00x | 1.03x | GBX-1.53 Million |
| 2020 | -60.83% | 0.00% | 0.00x | 1.12x | GBX-1.75 Million |
| 2021 | -27.48% | 0.00% | 0.00x | 1.10x | GBX-1.95 Million |
| 2022 | -112.82% | -3735.37% | 0.02x | 1.25x | GBX-3.04 Million |
| 2023 | -142.12% | -2146.91% | 0.05x | 1.30x | GBX-3.03 Million |
| 2024 | -96.84% | -237.88% | 0.23x | 1.76x | GBX-3.17 Million |
| 2025 | -7.39% | -15.01% | 0.38x | 1.29x | GBX-1.64 Million |
Industry Comparison
This section compares SkinBioTherapeutics PLC's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $10,807,025
- Average return on equity (ROE) among peers: -134.93%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| SkinBioTherapeutics PLC (SBTX) | GBX9.42 Million | -1.08% | 0.29x | $3.90K |
| 4BASEBIO UK SOCIETAS (4BB) | $11.70 Million | -27.66% | 0.26x | $10.53K |
| Aptamer Group PLC (APTA) | $8.05 Million | -26.00% | 0.43x | $3.12K |
| Arecor Therapeutics PLC (AREC) | $773.79K | -355.70% | 4.54x | $3.33K |
| Bioventix (BVXP) | $4.20 Million | 36.18% | 0.07x | $9.85K |
| Cizzle Biotechnology Holdings PLC (CIZ) | $741.00K | -0.02% | 3.16x | $747.56 |
| Fusion Antibodies PLC (FAB) | $1.46 Million | 79.21% | 0.28x | $2.07K |
| Faron Pharmaceuticals Oy (FARN) | $1.61 Million | -823.73% | 5.34x | $27.00K |
| Futura Medical (FUM) | $9.72 Million | -50.98% | 0.21x | $424.60 |
| hVIVO plc (HVO) | $2.86 Million | -195.31% | 2.17x | $5.18K |
| International Biotechnology Trust plc (IBT) | $66.95 Million | 14.71% | 0.00x | $1.10K |